Connie B Newman1, Michael J Blaha2, Jeffrey B Boord3, Bertrand Cariou4, Alan Chait5, Henry G Fein6, Henry N Ginsberg7, Ira J Goldberg1, M Hassan Murad8, Savitha Subramanian5, Lisa R Tannock9. 1. Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, New York University Grossman School of Medicine, New York, New York. 2. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. 3. Department of Administration and Parkview Physicians Group Endocrinology Section, Parkview Health System, Fort Wayne, Indiana. 4. Department of Endocrinology, L'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. 5. Department of Medicine, University of Washington, Seattle, Washington. 6. Department of Medicine, Division of Endocrinology, Sinai Hospital, Baltimore, Maryland. 7. Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. 8. Mayo Clinic Evidence-based Practice Center, Rochester, Minnesota. 9. Department of Internal Medicine, University of Kentucky, Lexington, Kentucky.
Abstract
OBJECTIVE: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. CONCLUSION: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.
OBJECTIVE: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. CONCLUSION: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.
Authors: Miguel Cainzos-Achirica; Isaac Acquah; Zeina Dardari; Reed Mszar; Philip Greenland; Ron Blankstein; Marcio Bittencourt; Sanjay Rajagopalan; Sadeer G Al-Kindi; Joseph F Polak; Roger S Blumenthal; Michael J Blaha; Khurram Nasir Journal: Am J Cardiol Date: 2021-12-15 Impact factor: 2.778
Authors: Daniel Bengtsson; Oskar Ragnarsson; Katarina Berinder; Per Dahlqvist; Britt Edén Engström; Bertil Ekman; Charlotte Höybye; Jacob Järås; Stig Valdemarsson; Pia Burman; Jeanette Wahlberg Journal: J Endocr Soc Date: 2022-03-18
Authors: Abel A Pavía-López; Marco A Alcocer-Gamba; Edith D Ruiz-Gastelum; José L Mayorga-Butrón; Roopa Mehta; Filiberto A Díaz-Aragón; Jorge A Aldrete-Velasco; Nitzia López-Juárez; Ivette Cruz-Bautista; Adolfo Chávez-Mendoza; Nikos C Secchi-Nicolás; Francisco J Guerrero-Martínez; Jorge E Cossio-Aranda; Victoria Mendoza-Zubieta; Guillermo Fanghänel-Salmon; Martha Valdivia-Proa; Luis Olmos-Domínguez; Carlos A Aguilar-Salinas; Luis Dávila-Maldonado; Armando Vázquez-Rangel; Vanina Pavia-Aubry; María de Los A Nava-Hernández; Carlos A Hinojosa-Becerril; Juan C Anda-Garay; Manuel O de Los Ríos-Ibarra; Ana C Berni-Betancourt; Julio López-Cuellar; Diego Araiza-Garaygordobil; Romina Rivera-Reyes; Gabriela Borrayo-Sánchez; Mónica Tapia-Hernández; Claudia V Cano-Nigenda; Arturo Guerra-López; Josué Elías-López; Marco A Figueroa-Morales; Bertha B Montaño-Velázquez; Liliana Velasco-Hidalgo; Ana L Rodríguez-Lozano; Claudia Pimentel-Hernández; María M Baquero-Hoyos; Felipe Romero-Moreno; Mario Rodríguez-Vega Journal: Arch Cardiol Mex Date: 2022
Authors: Stephanie T Chung; Samantha T Matta; Abby G Meyers; Celeste K Cravalho; Alfredo Villalobos-Perez; Joshua M Dawson; Vandhna R Sharma; Maureen L Sampson; James D Otvos; Sheela N Magge Journal: Front Endocrinol (Lausanne) Date: 2021-05-18 Impact factor: 5.555